Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC

Dogan I., Karyagar S., Karyagar S. S., Kahraman C., ALVER A.

ANNALS OF NUCLEAR MEDICINE, cilt.28, sa.9, ss.829-835, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 9
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12149-014-0877-y
  • Dergi Adı: ANNALS OF NUCLEAR MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.829-835
  • Anahtar Kelimeler: Cyfra 21.1, CEA, FDG PET, MTV, TLG, Tumor burden, CELL LUNG-CANCER, RECURRENT COLORECTAL-CANCER, NEURON-SPECIFIC ENOLASE, VOLUME-BASED PARAMETERS, BARR-VIRUS DNA, CARCINOEMBRYONIC ANTIGEN, PROGNOSTIC-SIGNIFICANCE, NASOPHARYNGEAL CARCINOMA, F-18-FDG PET/CT, FDG PET/CT
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Objective No investigation has been conducted on the association between PET findings and serum Cyfra 21.1 and CEA levels in nonsmall cell lung cancers (NSCLC). The purpose of this study is to find out if the serum levels of Cyfra 21.1 and CEA are related to metabolic parameters by FDG PET in patients with NSCLC who had not received treatment.